LAG3 Expression in Triple Negative Breast Cancer
Recruiting · NCT06259162 · Interventional (participants receive a specific treatment)
View the official record on ClinicalTrials.gov →Interventions studied
LAG-3 expression / immune checkpoint protein expression
What this trial is about
This study is the experimental study for relationship between LAG-3 expression / immue checkpoint protein expression and neoadjuvant chemotherapy plus immune checkpoint inhibitor in triple negative breast cancer.
Who can take part
Age range
No age limits stated
Sex
Female
Healthy volunteers
Yes - healthy volunteers may be accepted
Phase
Not applicable (e.g. observational or device study)
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Planned neoadjuvant chemotherapy
- Triple negative breast cancer
Exclusion criteria
- HER2-positive breast cancer
- Hormone receptor positive breast cancer
Where it is running
1 location listed.
- Ji-Yeon Kim - Seoul, South Korea